Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01583374




Registration number
NCT01583374
Ethics application status
Date submitted
20/04/2012
Date registered
24/04/2012

Titles & IDs
Public title
Study of Apremilast to Treat Subjects With Active Ankylosing Spondylitis
Scientific title
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE TREATMENT OF ACTIVE ANKYLOSING SPONDYLITIS
Secondary ID [1] 0 0
2011-001555-37
Secondary ID [2] 0 0
CC-10004-AS-001
Universal Trial Number (UTN)
Trial acronym
POSTURE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ankylosing Spondyloarthritis 0 0
Condition category
Condition code
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders
Inflammatory and Immune System 0 0 0 0
Rheumatoid arthritis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Apremilast tablet 20 mg
Treatment: Drugs - Apremilast tablet 30 mg BID
Treatment: Drugs - Placebo

Experimental: Apremilast 20 mg - Apremilast 20 mg was taken orally twice a day (BID)

Experimental: Apremilast 30 mg - Apremilast 30 mg was taken orally twice a day

Placebo comparator: Placebo - Identically matched placebo tablets were taken orally twice a day


Treatment: Drugs: Apremilast tablet 20 mg
Apremilast 20 mg was taken orally twice a day (BID)

Treatment: Drugs: Apremilast tablet 30 mg BID
Apremilast 30 mg was taken orally twice a day

Treatment: Drugs: Placebo
Identically matched placebo tablets were taken orally twice a day during the placebo controlled phase.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS 20) Response at Week 16
Timepoint [1] 0 0
Baseline and Week 16
Secondary outcome [1] 0 0
Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 24
Timepoint [1] 0 0
Baseline and Week 24
Secondary outcome [2] 0 0
Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) at Week 24
Timepoint [2] 0 0
Baseline and Week 24
Secondary outcome [3] 0 0
Percentage of Participants Who Achieved an Assessment of SpondyloArthritis International Society 20 (ASAS) Response at Week 24
Timepoint [3] 0 0
Baseline and Week 24
Secondary outcome [4] 0 0
Change From Baseline in the Ankylosing Spondylitis Quality of Life (ASQoL) Summary Score at Week 24
Timepoint [4] 0 0
Baseline and Week 24
Secondary outcome [5] 0 0
Change From Baseline in the Physical Component Summary Score (PCS) of Medical Outcome Study Short Form 36-Item Health Survey, Version 2 (SF-36) at Week 24
Timepoint [5] 0 0
Baseline and Week 24
Secondary outcome [6] 0 0
Change From Baseline in Bath Ankylosing Spondylitis Metrology Index-Linear (BASMI-Linear) at Week 24
Timepoint [6] 0 0
Baseline and Week 24
Secondary outcome [7] 0 0
Change From Baseline in the Radiographic Score Using the Modified Stoke Ankylosing Spondylitis Spine Score (m-SASSS) at Week 104 and Week 260
Timepoint [7] 0 0
Baseline to Week 104 and 260
Secondary outcome [8] 0 0
Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Placebo Controlled Phase
Timepoint [8] 0 0
From Week 0 to Week 24; the median duration of exposure was 23.57 weeks for the placebo arm, 23.71 weeks for the apremilast 20 mg arm and 24.00 weeks for the apremilast 30 mg arm.
Secondary outcome [9] 0 0
Number of Participants With Treatment Emergent Adverse Events During the Apremilast Exposure Period
Timepoint [9] 0 0
Week 0 to week 260; overall mean duration of exposure to apremilast 20 mg and 30 mg BID was 160.96 weeks

Eligibility
Key inclusion criteria
* Must have a documented diagnosis of ankylosing spondylitis as defined by low back pain and stiffness, which improves with exercise, but is not relieved by rest for more than 3 months prior to screening. At the completion of screening procedures, a documented diagnosis of definite active AS, as defined by the modified New York criteria (1984) whereby both criteria, at least 1 radiographic criterion and at least 1 clinical criterion, must be met
* Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) is = 4
* Total back pain is = 4
* On stable dose of AS medication (or lack of medication) prior to randomization and through week 24
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Prior treatment with a Tumor Necrosis Factor (TNF) blocker and any biologic treatment for AS

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
2/05/2012
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
25/10/2018
Sample size
Target
Accrual to date
Final
490
Recruitment in Australia
Recruitment state(s)
TAS,VIC
Recruitment hospital [1] 0 0
Southern Clinical Research - Hobart
Recruitment hospital [2] 0 0
Emeritus Research - Camberwell
Recruitment hospital [3] 0 0
Coastal Joint Care - Maroochydore
Recruitment hospital [4] 0 0
Royal Perth Hospital - Perth
Recruitment hospital [5] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment postcode(s) [1] 0 0
7000 - Hobart
Recruitment postcode(s) [2] 0 0
3124 - Camberwell
Recruitment postcode(s) [3] 0 0
4558 - Maroochydore
Recruitment postcode(s) [4] 0 0
6849 - Perth
Recruitment postcode(s) [5] 0 0
5011 - Woodville South
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Illinois
Country [5] 0 0
United States of America
State/province [5] 0 0
Maryland
Country [6] 0 0
United States of America
State/province [6] 0 0
Massachusetts
Country [7] 0 0
United States of America
State/province [7] 0 0
Minnesota
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Tennessee
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
United States of America
State/province [12] 0 0
Utah
Country [13] 0 0
United States of America
State/province [13] 0 0
Wisconsin
Country [14] 0 0
Austria
State/province [14] 0 0
Wien
Country [15] 0 0
Bulgaria
State/province [15] 0 0
Pleven
Country [16] 0 0
Bulgaria
State/province [16] 0 0
Sofia
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Varna
Country [18] 0 0
Canada
State/province [18] 0 0
Alberta
Country [19] 0 0
Canada
State/province [19] 0 0
Newfoundland and Labrador
Country [20] 0 0
Canada
State/province [20] 0 0
Ontario
Country [21] 0 0
Canada
State/province [21] 0 0
Quebec
Country [22] 0 0
Czechia
State/province [22] 0 0
Brno
Country [23] 0 0
Czechia
State/province [23] 0 0
Hostivice
Country [24] 0 0
Czechia
State/province [24] 0 0
Pardubice
Country [25] 0 0
Czechia
State/province [25] 0 0
Praha 11
Country [26] 0 0
Czechia
State/province [26] 0 0
Praha 4
Country [27] 0 0
Czechia
State/province [27] 0 0
Praha
Country [28] 0 0
Czechia
State/province [28] 0 0
Sokolov
Country [29] 0 0
Czechia
State/province [29] 0 0
Zlin
Country [30] 0 0
Estonia
State/province [30] 0 0
Tallinn
Country [31] 0 0
Estonia
State/province [31] 0 0
Tartu
Country [32] 0 0
France
State/province [32] 0 0
Boulogne
Country [33] 0 0
France
State/province [33] 0 0
Créteil
Country [34] 0 0
France
State/province [34] 0 0
Orléans Cedex 2
Country [35] 0 0
France
State/province [35] 0 0
Paris
Country [36] 0 0
Germany
State/province [36] 0 0
Berlin
Country [37] 0 0
Germany
State/province [37] 0 0
Erlangen
Country [38] 0 0
Germany
State/province [38] 0 0
Frankfurt
Country [39] 0 0
Germany
State/province [39] 0 0
Hamburg
Country [40] 0 0
Germany
State/province [40] 0 0
Heidelberg
Country [41] 0 0
Germany
State/province [41] 0 0
Herne
Country [42] 0 0
Hungary
State/province [42] 0 0
Budapest
Country [43] 0 0
Hungary
State/province [43] 0 0
Debrecen
Country [44] 0 0
Hungary
State/province [44] 0 0
Kistarcsa
Country [45] 0 0
Hungary
State/province [45] 0 0
Veszprém
Country [46] 0 0
Netherlands
State/province [46] 0 0
Leiden
Country [47] 0 0
Netherlands
State/province [47] 0 0
Maastricht
Country [48] 0 0
Poland
State/province [48] 0 0
Bialystok
Country [49] 0 0
Poland
State/province [49] 0 0
Bydgoszcz
Country [50] 0 0
Poland
State/province [50] 0 0
Gdynia
Country [51] 0 0
Poland
State/province [51] 0 0
Lublin
Country [52] 0 0
Poland
State/province [52] 0 0
Poznan
Country [53] 0 0
Poland
State/province [53] 0 0
Torun
Country [54] 0 0
Poland
State/province [54] 0 0
Wroclaw
Country [55] 0 0
Romania
State/province [55] 0 0
Braila
Country [56] 0 0
Romania
State/province [56] 0 0
Bucharest
Country [57] 0 0
Romania
State/province [57] 0 0
Cluj-Napoca
Country [58] 0 0
Romania
State/province [58] 0 0
Galati
Country [59] 0 0
Romania
State/province [59] 0 0
Iasi
Country [60] 0 0
Russian Federation
State/province [60] 0 0
Ekaterinburg
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Kazan
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Kemerovo
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Moscow
Country [64] 0 0
Russian Federation
State/province [64] 0 0
Nizhniy Novgorod
Country [65] 0 0
Russian Federation
State/province [65] 0 0
Smolensk
Country [66] 0 0
Russian Federation
State/province [66] 0 0
Vladimir
Country [67] 0 0
Slovakia
State/province [67] 0 0
Piestany
Country [68] 0 0
Slovakia
State/province [68] 0 0
Poprad
Country [69] 0 0
Spain
State/province [69] 0 0
A Coruña
Country [70] 0 0
Spain
State/province [70] 0 0
Barcelona
Country [71] 0 0
Spain
State/province [71] 0 0
Cordoba
Country [72] 0 0
Spain
State/province [72] 0 0
Madrid
Country [73] 0 0
Spain
State/province [73] 0 0
Sabadell
Country [74] 0 0
Spain
State/province [74] 0 0
Santiago de Compostela
Country [75] 0 0
Sweden
State/province [75] 0 0
Malmö
Country [76] 0 0
United Kingdom
State/province [76] 0 0
Barnsley
Country [77] 0 0
United Kingdom
State/province [77] 0 0
Bath
Country [78] 0 0
United Kingdom
State/province [78] 0 0
Leeds
Country [79] 0 0
United Kingdom
State/province [79] 0 0
Oxford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Amgen
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
MD
Address 0 0
Amgen
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
When will data be available (start and end dates)?
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Available to whom?
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Available for what types of analyses?
How or where can data be obtained?
IPD available at link: http://www.amgen.com/datasharing


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results are available at https://clinicaltrials.gov/study/NCT01583374